TABLE 1.
Details of experiment 1a
| Group no. | Pretreatment | No. of mice per group | PHH donor and no. of PHHs per transplant | huAlb (mg/mL)b | HBV status and antiviral therapy |
|---|---|---|---|---|---|
| 1 | MCT | 10 | A, 5 × 105 | Fig. 1B | 1, uninfected/untreated |
| 5, infected + ETV treatment | |||||
| 4, infected + ETV+CPX treatment | |||||
| 2 | Anti-CD95 MAb | 10 | A, 5 × 105 | Fig. 1B | 1, uninfected/untreated |
| 4, infected + ETV treatment | |||||
| 3, infected + ETV+CPX treatment | |||||
| 3 | MCT | 10 | B, 5 × 105 | Fig. 1B | 1, uninfected/untreated |
| 4, infected + ETV treatment | |||||
| 5, infected + ETV+CPX treatment | |||||
| 4 | Anti-CD95 MAb | 10 | B, 5 × 105 | Fig. 1B | 1, uninfected/untreated |
| 3, infected + ETV treatment | |||||
| 3, infected + ETV+CPX treatment |
a
In this experiment, a total of 34/40 male mice survived the transplant procedure and had detectable huAlb in serum. These are the mice from the experiments shown in Fig. 1B, Fig. 2A to G, Fig. 6A to H, Fig. 7A to D, and Fig. 8A to D. An experimental timeline for these mice is shown in Fig. 6A. huAlb levels were measured at 12 weeks post-PHH transplant.
b
Data are shown in the cited figure.